Lysine aspirin for injection

This product is a complex salt of aspirin and lysine, which can inhibit cyclooxygenase, reduce the synthesis of prostaglandins, and has antipyretic, analgesic and anti-inflammatory effects.

The main ingredients of this product are: Lysine

Used for fever and mild to moderate pain.

For intramuscular or intravenous injection, dissolve in 4 ml of water for injection or 0.9% sodium chloride injection and inject. (1) Adults: 0.9-1.8 g at a time, twice a day. (2) Children: 10-25 mg/kg per day, divided into 2 doses.

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), there is a risk of increasing bleeding. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this drug is already stable may lead to an increase in the blood drug concentration of this drug and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this drug when used together, the dose of this drug should be increased if necessary. Long-term use of this drug with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this drug together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this drug at the same time; when the blood concentration of salicylate is greater than 50μg/ml, it is significantly reduced, and it is even more so when it is greater than 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.

It should not be used in the following situations: active peptic ulcer or gastrointestinal bleeding caused by other reasons; hemophilia or thrombocytopenia; those with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, angioedema or shock.

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), there is a risk of increasing bleeding. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this drug is already stable may lead to an increase in the blood drug concentration of this drug and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this drug when used together, the dose of this drug should be increased if necessary. Long-term use of this drug with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this drug together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this drug at the same time; when the blood concentration of salicylate is greater than 50μg/ml, it is significantly reduced, and it is even more so when it is greater than 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.

Sealed, store in a cool, dry place.

0.5g

Hainan Tongyong Kangli Pharmaceutical Co., Ltd.

• Founded in:

  2000-05-16

• Address:

  Room 221-226, Building 1, No. 269, Nanhai Avenue, National High-tech Industrial Development Zone, Haikou City, Hainan Province

• Tax NO.:

  914600007212236930

• Registered Funds:

  50 million yuan

• Email:

  Log in to view